EXPERIMENTAL ANALYSIS OF SAFETY OF ISOFLURANE LONG-TERM USE IN A CLOSED LOOP
Relevance. The main problem with the use of inhalation anesthetics in a closed loop is the interaction of halogen-containing preparations with a carbon dioxide absorber, as a result of which volatile toxic substances are released. There are several options to ensure the safety of anesthesia, one of which may be a decrease in the content of anesthetic in the gas mixture.
The purpose of the study is to experimentally test the safety hypothesis of a long-term exposure of a halogen-containing anesthetic in closed-loop mode with its low content in the respiratory mixture.
Materials and methods. Design: An experimental, controlled, prospective study. An experimental study was conducted on 40 weekly, white outbred rats, males, weighing from 190 to 220 g (average weight 201±7 g). A total of 3 series of experiments were carried out using 10 animals in each, 10 were included in the control group. In Series I, the duration of anesthesia was 4 hours, in Series II, 10 hours and in Series III, 16 hours. Inhalation anesthesia was performed using the anesthetic of isoflurane in a closed loop (carbon dioxide absorber) with an isoflurane vapor concentration in the closed loop of 0.3-0.5 vol.% And oxygen (50% in the inhaled mixture). Liver and kidney tissues were subjected to morphological analysis. The studies included determination of total protein in the blood, albumin, urea, creatinine, daily diuresis, including relative, daily excretion of protein and creatinine. Immunological studies included the determination of interleukins (TNFα, IL-2, IL-6, IL-10) and leukocytes of various differentiation clusters (common, CD3+, CD4+, CD8+, CD19+, CD95+). Parametric (Student's t-test) and non-parametric (Mann-Whitney or Wilcoxon tests) methods of statistical analysis were used.
Results. There were no significant and statistically significant differences in the main blood biochemical parameters in experimental animals during any of the examination periods, as well as changes in absolute and relative daily diuresis, increased protein excretion and changes in creatinine excretion, which completely eliminates the formation of renal failure as a result of prolonged exposure anesthetics in a closed loop.
In addition, throughout the entire study period, no signs of acute inflammatory processes or a decrease in immunological parameters were found.
Conclusion The results of the study indicate the complete safety of prolonged use of inhalation anesthesia with isoflurane in with the inclusion of carbon dioxide absorber in the circuit with the use of minimal concentrations (0.3-0.5%) of the drug in the mixture.
Sayat Z. Tanatarov, https://orcid.org/0000-0001-8958-8768
Department of Clinical and Radiation Oncology,
NAC "Semey Medical University",
Semey, Republic of Kazakhstan
1. Қазақстан Республикасы Денсаулық сақтау Министрлігінің 2007 жылдың 25 шілдедегі №442 «Қазақстан Респуликасындағы клиникаға дейінгі, медициналық - биологиялық эксперименттерді және клиникалық сынақтарды жүргізу туралы Ережесіне». – Астана, 2007 (Rules for conducting preclinical, biomedical experiments and clinical trials in the Republic of Kazakhstan of the Ministry of Health of the Republic of Kazakhstan. - July 25, 2007 No. 442).
2. Baum J., Stanke H.G. Low-flow and minimal-flow anesthesia with sevoflurane. Anaesthesist. 1998 Nov;47 Suppl 1:S70-76.
3. Brattwall M, Warrén-Stomberg M, Hesselvik F, Jakobsson J. Brief review: theory and practice of minimal fresh gas flow anesthesia. Can J Anaesth. 2012 Aug;59(8):785-797.
4. Chelazzi C. Sevoflurane: going beyond anesthesia, cardiac conditioning and organ toxicity. Minerva Anestesiol. 2014 Jun; 80(6):629-631.
5. Costa R., Costa R.B., Talamantes S.M., et al. Meta-analysis of selected toxicity endpoints of CDK4/6 inhibitors: Palbociclib and ribociclib. Breast. 2017 Oct;35:1-7.
6. Directive 2010/63/EU of the European Parliament and the Council of the Office on the protection of animals used for scientific purposes of 22 September 2010 // Official Journal of the European Union. 2010. L. 276. P. 33-79.
7. Doyle D.J. Airway anesthesia: theory and practice. Anesthesiol Clin. 2015 Jun;33(2):291-304.
8. Feldman J.M., Lo C., Hendrickx J. Estimating the Impact of Carbon Dioxide Absorbent Performance Differences on Absorbent Cost During Low-Flow Anesthesia. Anesth Analg. 2019 Mar 27. 257-165
9. Forget P., Collet V., Lavand'homme P., De Kock M. Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol. 2010 Mar;27(3):233-240.
10. Gallego L., Soro M., Alvariño A., Noguera I., Belda F.J. Renal and hepatic integrity in long-term sevoflurane sedation using the anesthetic conserving device: a comparison with intravenous propofol sedation in an animal model. Rev Esp Anestesiol Reanim. 2015 Apr;62(4):191-203.
11. Glantz S.A. Primer of Biostatistics. McGRAW-HILL. Health Professions Division. 1999. – 488 p.
12. Gonsowski C., Laster M., Eger E. et al. Toxicity of Compound A in Rats. Anesthesiology. 1994;80(3):556-565.
13. Grigoliia G.N., Makhatadze T.A., Sulakvelidze K.R., Tutberidze K.N., Gvelesiani L.G. Theory and practice of low-flow anaesthesia. Georgian Med News. 2007 Apr;(145):7-12.
14. Hayes A.W., Dixon D. Cornerstones of Toxicology. Toxicol Pathol. 2017 Jan;45(1):57-63.
15. Iyer R., Anders M. Cysteine Conjugate.-Lyase-Dependent Biotransformation of the Cysteine SConjugates of the Sevoflurane Degradation Product Compound A in Human, Non-Human Primate, and Rat Kidney Cytosol and Mitochondria. Anesthesiology. 1996;85(6):1454-1461.
16. Järup L. Hazards of heavy metal contamination. Br Med Bull 2003. 68:167–182.
17. Le Guen M., Liu N., Chazot T., Fischler M. Closed-loop anesthesia. Minerva Anestesiol. 2016 May;82(5):573-581.
18. McCann M.E., de Graaff J. Current thinking regarding potential neurotoxicity of general anesthesia in infants. Curr Opin Urol. 2017 Jan;27(1):27-33.
19. Moran P., Barr D., Holmes C. Saving sevoflurane: Automated gas control can reduce consumption of anesthetic vapor by one-third in pediatric anesthesia. Paediatr Anaesth. 2019 Apr;29(4):310-314.
20. Nebert D.W., Shi Z., Gálvez-Peralta M., Uno S., Dragin N. Oral benzo[a]pyrene: understanding pharmacokinetics, detoxication, and consequences – Cyp1 knockout mouse lines as a paradigm. Mol Pharmacol. 2013 Sep;84(3):304-313.
21. Odin I., Feiss P. Low flow and economics of inhalational anaesthesia. Best Pract Res Clin Anaesthesiol. 2005 Sep;19(3):399-413.
22. Petersen C., Wetterslev J., Meyhoff C.S. Perioperative hyperoxia and post-operative cardiac complications in adults undergoing non-cardiac surgery: Systematic review protocol. Acta Anaesthesiol Scand. 2018 Aug;62(7):1014-1019.
23. Sarikus Z., Bedirli N., Yilmaz G., Bagriacik U., Bozkirli F. The effects of epidural bupivacaine on ischemia/reperfusion-induced liver injury. Bratisl Lek Listy. 2016;117(1):41-46.
24. Stephens M.L., Betts K., Beck N.B. et al. The Emergence of Systematic Review in Toxicology. Toxicol Sci. 2016 Jul;152(1):10-16.
25. Stollings L.M., Jia L.J., Tang P., Dou H., Lu B., Xu Y. Immune Modulation by Volatile Anesthetics. Anesthesiology. 2016 Aug;125(2):399-411.
26. Upadya M, Saneesh PJ. Low-flow anaesthesia - underused mode towards "sustainable anaesthesia". Indian J Anaesth. 2018 Mar;62(3):166-172.
27. Wetz A.J., Mueller M.M., Walliser K. et al. End-tidal control vs. manually controlled minimal-flow anesthesia: a prospective comparative trial. Acta Anaesthesiol Scand. 2017 Nov; 61(10):1262-1269.
Number of Views: 239
Category of articles:
Original articles
Bibliography link
Танатаров С.З. Экспериментальный анализ безопасности длительного применения изофлюрана в закрытом контуре // Наука и Здравоохранение. 2019. 2 (Т.21).С. 76-82. Tanatarov S.Z. Experimental analysis of safety of isoflurane long-term use in a closed loop // Nauka i Zdravookhranenie [Science & Healthcare]. 2019, (Vol.21) 2, pp. 76-82. Танатаров С.З. Жабық контурда изофлюранды ұзақ қолданудың қауіпсіздігін эксперименталды талдау // Ғылым және Денсаулық сақтау. 2019. 2 (Т.21). Б. 76-82.Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS